© Copyright Our Wall
Roots Analysis is pleased to announce
the publication of its recent study, titled, “Rare Kidney Disorders Market, 2022–2035”.
Over 25 total
pipeline candidates are available in the market across various geographical
regions. Of these, 43% have been approved for the treatment of cystinosis, Fabry diseaseand lupus nephritis. Further, majority
of the approved / under development drugs (47%) are designed for delivery via
oral route.
The report
features an extensive study of the current market landscape and the likely
future potential associated with the rare kidney disorders market, over the
next decade.
To request a sample copy / brochure of
this report, please visit
https://www.rootsanalysis.com/reports/rare-kidney-diseases-market/request-sample.html
The study also
features an in-depth analysis, highlighting the capabilities of various
industry stakeholders engaged in this field. Amongst other elements, the report
features:
§ A detailed executive summary of key
insights captured during our research. It offers a high-level view on the current
state of rare kidney disorders market and its likely evolution in the mid to
long term.
§ A
brief introduction to various aspects of rare kidney disorders. It includes a
detailed discussion on the historical evolution and factors contributing to the
treatment of rare kidney disorders. Further, it highlights various prominent
target indications associated with rare kidney disorders, application of omics
technology and its future perspectives.
§ A
detailed overview of the current market landscape of more than 125 drug candidates that are either approved or
currently under development for the treatment of various rare kidney disorders,
based on several relevant parameters, such as phase of development (approved,
registration, phase III, phase II, phase I, pre-clinical and discovery), target
molecule (complement component 5 (C5), complement component 3 (C3), a
proliferation-inducing ligand (APRIL), B lymphocyte stimulator (BLyS),
Complement Factor B, and others), route of administration (oral, intravenous,
subcutaneous, and others), and target indication (complement 3 glomerulopathy
(C3G), focal segmental glomerular sclerosis (FSGS), IgA nephropathy (IgAN),
lupus nephritis (LN), membranous nephropathy (MN)), type of molecule (biologics
and small molecules), and type of biologic (monoclonal antibody (mAb), hormone,
recombinant protein, enzyme replacement therapy (ERT), gene therapy, small
interfering ribonucleic acid (siRNA) molecule and others). In addition, it
presents details of the companies engaged in the development of drugs targeting
rare kidney disorders, based on several relevant parameters, such as year of
establishment, company size (in terms of number of employees), location of
headquarters, and most active players.
§ Elaborate
profiles of approved and clinical stage drugs indicated for rare kidney
disorders (phase II / III or above). Each profile features an overview of the
drug developer, clinical trial information related to the drug, clinical trial
results, and estimated sales revenues (if available).
§ A
detailed competitiveness analysis of companies engaged in the development of
rare kidney disorders targeting drugs, based on their developer strength (in
terms of years of experience), portfolio strength (in terms of number of drugs
developed), and portfolio diversity (in terms of phase of development, target
indication, and drug designation).
§ An
in-depth analysis of the various collaborations and partnerships that have been
inked by players engaged in the development of drugs targeting various rare
kidney disorders since 2017, based on several relevant parameters, such as year
of partnership, type of partnership, focus area, type of partner and regional
distribution of partnerships.
§ An
analysis of the funding and investments made within the domain, during the
period 2016-2022, based on several relevant parameters, such as year of
funding, type of funding (seed financing, venture capital financing, debt
financing, grants, IPOs and other offerings), leading players (in terms of
amount invested) and key investors (in terms of number of funding instances).
§ A
detailed clinical trial analysis of ongoing clinical studies for the evaluation
of various drug candidates targeting rare kidney disorders, based on several
relevant parameters, such as trial registration year, current trial status,
phase of development, key target indications, patient age, study design and key
geographical regions.
§ A
detailed analysis of the clinical and commercial attractiveness for drugs
targeting rare kidney disorders, based on several relevant parameters, such as
target patient population, dosing frequency and dose strength.
§ A
case study highlighting the companies engaged in offering kidney care services,
along with information on their year of establishment, company size (in terms of
number of employees), location of headquarters and target indication.
The financial opportunity
within the rare kidney disorders market has been analysed across the following segments:
§ Type of Molecule
§ Small Molecules
§ Biologics
§ Route of Administration
§ Oral Delivery
§ Intravenous Delivery
§ Subcutaneous Delivery
§ Other Delivery Routes
§ Target Indications
§ Atypical Hemolytic Uremic Syndrome
§ C3 glomerulopathy
§ Cystinosis
§ Dense Deposit Disease
§ distal Renal Tubular Acidosis
§ Fabry disease
§ IgA nephropathy
§ Lupus Nephritis
§ Refractory Gout
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the World
For more information,
please click on the following link:
https://www.rootsanalysis.com/reports/rare-kidney-diseases-market.html
You may also be interested in the
following titles:
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market
research. Having worked with over 750 clients worldwide, including Fortune 500
companies, start-ups, academia, venture capitalists and strategic investors for
more than a decade, we offer a highly analytical / data-driven perspective to a
network of over 450,000 senior industry stakeholders looking for credible
market insights.
Contact:
Ben Johnson
+1 (415) 800
3415
[email protected]
The Wall